BEAM vs PRME: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

BEAM is the larger of the two ($2.54B market cap): the incumbent the market prices for continued execution (-4.89x forward earnings, beta 2.22). PRME is the smaller challenger ($708.28M), priced similarly on forward earnings (-4.32x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

BEAM vs PRME: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricBEAMPRMEWhat it tells you
Market cap$2.54B$708.28MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-4.89-4.32Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta2.222.15Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range24% of range38% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.5617.36How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how BEAM and PRME affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BEAM and PRME share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BEAM and PRME exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Beam Therapeutics (BEAM) do?

Beam Therapeutics (NASDAQ: BEAM) develops precision genetic medicines using base editing, a technique it helped invent that rewrites a single letter of DNA without cutting both strands of the double helix, aiming for more precise fixes than first-generation CRISPR. Its pipeline spans risto-cel (formerly BEAM-101) for sickle cell disease, with a biologics license application targeted as early as year-end 2026, plus BEAM-302 for alpha-1 antitrypsin deficiency, and BEAM-301 and BEAM-304 for rare liver-mediated genetic diseases. The company also runs collaborations with partners including Pfizer and Eli Lilly, which supply most of its reported revenue through upfront payments and milestones.

Full BEAM guide

What does Prime Medicine (PRME) do?

Prime Medicine is a gene-editing company developing therapies based on prime editing, a technology that pairs a CRISPR-derived nickase with a reverse transcriptase to make targeted search-and-replace edits to DNA without cutting both strands. The platform is positioned to address a broad range of genetic mutations and to deliver one-time treatments, but as of 2026 the company has no approved products and no product revenue. Its economics are typical of clinical-stage biotech: heavy research and development spending, recurring net losses, and reliance on cash reserves, partnerships, and equity raises to fund operations. The second half of 2026 moved the story from preclinical to clinical: the FDA cleared the Investigational New Drug application for PM647 in Alpha-1 Antitrypsin Deficiency on September 24, 2026, and the first patient was dosed in a global Phase 1/2 trial of PM577a for H1069Q-mutated Wilson Disease on October 5, 2026. In Q2 2026 the company reported ~$1.15 million of collaboration revenue and a ~$42.1 million net loss (EPS ~-$0.24 versus a ~-$0.26 estimate). The shares rose ~11.2% over the month to October 16, 2026, closing at ~$3.47, but remain down ~1.7% for the year and ~40.2% over twelve months.

Full PRME guide

BEAM vs PRME: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • BEAM drivers: Risto-cel sickle cell path to filing; In vivo liver franchise.
  • PRME drivers: Narrowed focus on a liver franchise; Lead asset and FDA engagement.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Beam is pre-commercial and deeply unprofitable, so it carries the full binary risk of a clinical-stage biotech: a single failed trial, safety signal, or regulatory setback can reset the stock. For PRME, prime Medicine is pre-revenue and burns tens of millions of dollars per quarter, so the central risks are clinical and financial.

BEAM or PRME: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BEAM if you believe its drivers more; PRME if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BEAM and PRME guides.

BEAM vs PRME: the full fundamentals

BEAM. Beam's revenue is collaboration and milestone income, not product sales, so it is lumpy (about $114 million in the fourth quarter of 2025, zero in the second quarter of 2026) and not comparable to a profitable company's top line. With no approved therapy and heavy R&D spending, the company runs large net losses funded by its cash pile. At about $2.5 billion as of October 16, 2026, the market value is roughly twice the cash balance, so the valuation reflects a modest, probability-weighted view of the pipeline.

PRME. Prime Medicine is not profitable and is valued on its pipeline rather than earnings; a price-to-sales ratio near ~155x on collaboration revenue says little. The relevant numbers are cash against burn and the timing of the first clinical data from PM577a and PM647, which entered the clinic in September and October 2026. Figures are approximate as of October 16, 2026; check the latest filings for current numbers.

Headline figures (approximate, October 2026): BEAM shows market cap ~$2.5B, revenue (ttm, collaboration) ~$156M, revenue (q2 2026) ~$0, net loss (q2 2026) ~$123M; PRME shows product revenue None; collaboration revenue ~$4.1 million trailing twelve months (~$1.15 million in Q2 2026), net loss ~$187.9 million trailing; Q2 2026 net loss ~$42.1 million (EPS ~-$0.24 versus a ~-$0.26 estimate), cash and debt (june 30, 2026) ~$95.1 million cash and equivalents against ~$112.5 million of debt, cash burn Operating cash flow ~-$156 million trailing twelve months.

The bottom line: BEAM vs PRME

BEAM and PRME are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BEAM and PRME exposure against your real portfolio. It is not an investment adviser.

Wondering how BEAM or PRME fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Beam Therapeutics

Ask Walnut's AI anything about BEAM and see how it fits what you own.

FAQ

What is the difference between BEAM and PRME?

+

Beam Therapeutics (NASDAQ: BEAM) develops precision genetic medicines using base editing, a technique it helped invent that rewrites a single letter of DNA without cutting both strands of the double helix, aiming for more precise fixes than first-generation CRISPR. Prime Medicine is a gene-editing company developing therapies based on prime editing, a technology that pairs a CRISPR-derived nickase with a reverse transcriptase to make targeted search-and-replace edits to DNA without cutting both strands. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is BEAM or PRME the better stock?

+

Neither is universally better. BEAM is the larger incumbent; PRME is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, BEAM or PRME?

+

On forward P/E (as of November 2026), BEAM trades at -4.89x and PRME at -4.32x, so BEAM is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both BEAM and PRME?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of BEAM vs PRME?

+

BEAM: Beam is pre-commercial and deeply unprofitable, so it carries the full binary risk of a clinical-stage biotech: a single failed trial, safety signal, or regulatory setback can reset the stock. Gene and cell therapies face complex manufacturing, long timelines, and uncertain pricing and reimbursement even after approval. Despite a large cash balance, sustained losses mean future capital raises and shareholder dilution are plausible. The company competes in a crowded gene-editing field, and sector-wide sentiment can pressure the shares regardless of Beam's own progress. There is no guarantee any program reaches the market. Litigation is now part of the picture too: Beam's September 2026 trade-secret suits against two biotechs could take years and cost money, with uncertain outcomes. PRME: Prime Medicine is pre-revenue and burns tens of millions of dollars per quarter, so the central risks are clinical and financial. As of March 31, 2026 the company reported roughly ~$149.2 million in cash, cash equivalents, investments, and restricted cash, which management expected to fund operations into 2027; by June 30, 2026 cash and equivalents stood near ~$95.1 million against ~$112.5 million of debt, and trailing operating cash burn was ~$156 million, implying that another financing will likely be needed and could dilute existing shareholders. Lead programs only entered the clinic in September and October 2026, so a failed readout, a delayed filing, or a safety setback could materially reduce the company's value. It also competes with better-capitalized gene-editing peers, some of which already have approved or later-stage products. Sentiment across gene editing is also volatile: in late September 2026 PRME, CRSP, NTLA, BEAM and EDIT all slipped on reports about AI-driven discovery tools before rebounding.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BEAM or PRME; figures are approximate and dated (as of November 2026). Verify current data before investing.